Nasal high-flow bronchodilator nebulization: a randomized cross-over study

François Reminiac1,2,3, Laurent Vecellio2, Laetitia Bodet-Contentin1,4,5, Valérie Gissot4, Deborah Le Pennec2, Charlotte Salmon Gandonnière1,4,5, Maria Cabrera2, Pierre-François Dequin1,2,4,5, Laurent Plantier2,6 and Stephan Ehrmann1,2,4,5*

Abstract

Background: There is an absence of controlled clinical data showing bronchodilation effectiveness after nebulization via nasal high-flow therapy circuits.

Results: Twenty-five patients with reversible airflow obstruction received, in a randomized order: (1) 2.5 mg albuterol delivered via a jet nebulizer with a facial mask; (2) 2.5 mg albuterol delivered via a vibrating mesh nebulizer placed downstream of a nasal high-flow humidification chamber (30 L/min and 37 °C); and (3) nasal high-flow therapy without nebulization. All three conditions induced significant individual increases in forced expiratory volume in one second (FEV1) compared to baseline. The median change was similar after facial mask nebulization [+350 mL (+180; +550); +18% (+8; +30)] and nasal high flow with nebulization [+330 mL (+140; +390); +16% (+5; +24)], p = 0.11. However, it was significantly lower after nasal high-flow therapy without nebulization [+50 mL (−10; +220); +3% (−1; +8)], p = 0.0009. FEV1 increases after facial mask and nasal high-flow nebulization as well as residual volume decreases were well correlated (p < 0.0001 and p = 0.01). Both techniques showed good agreement in terms of airflow obstruction reversibility (kappa 0.60).

Conclusion: Albuterol vibrating mesh nebulization within a nasal high-flow circuit induces similar bronchodilation to standard facial mask jet nebulization. Beyond pharmacological bronchodilation, nasal high flow by itself may induce small but significant bronchodilation.

Keywords: Albuterol, Respiratory function tests, Nebulizers and vaporizers, Chronic obstructive pulmonary disease

Background

Nasal high-flow (NHF) therapy consists of delivering heated and humidified gas through a nasal cannula, at high flow rates, frequently exceeding patients’ inspiratory flow. This non-invasive respiratory support is increasingly used, particularly among hypoxemic critically ill patients as those high oxygen flow rates very efficiently improve oxygenation and reduce the rate of intubation [1, 2]. Nebulization is a technique used to deliver inhaled drugs directly acting on the respiratory tract. In critically ill patients, nebulization is very frequently used, in particular among patients undergoing non-invasive respiratory support [3]. The most frequently delivered inhaled drugs are bronchodilators, such as albuterol, provided to approximately 20% of patients in intensive care [3]. Thus, one may question the best way to combine the two therapies in order to deliver inhaled bronchodilators to patients undergoing NHF therapy. Indeed, NHF may be especially beneficial to patients suffering obstructive pulmonary disease for whom inhaled bronchodilator delivery is a cornerstone of therapy [4–6]. NHF washes out the anatomical dead space clearing exhaled carbon dioxide, and this may have benefit to patients with hypercapnia [7, 8]; it induces a positive end-expiratory pressure, a reduction in respiratory rate and increase in tidal volume, which all potentially lead to a reduction in the work of breathing among patients with dynamic
hyperinflation [9, 10]; it enables precise control of the inspired fraction of oxygen to avoid excessive delivery among patients with chronic hypercapnia and altered respiratory drive; it ensures high humidification of inhaled gases favouring mucus hydration and thus clearance and is a very well-tolerated oxygen delivery method. Nevertheless, NHF merely represents an obstacle impeding inhaled drug delivery. Indeed, high gas flow rate and associated turbulent flow, high gas humidity, geometric angulation of the nasal cannula, and the nose anatomy physiologically retaining inhaled particles all represent hurdles to efficient inhaled drug delivery through an NHF circuit. In vitro data showed that when placing a vibrating mesh nebulizer close to the humidification chamber and limiting the system flow rate at 30 L/min, significant amounts of drug may be delivered to the respiratory tract [11–15]. That data have been confirmed by in vivo evaluation in a paediatric animal model and in adult radiolabelled deposition studies [16, 17]. Although uncontrolled case series are in favour of a clinically significant bronchodilation after delivery of albuterol through an NHF circuit, no controlled data are available in humans [18].

The objective of this study was to investigate the effect of vibrating mesh nebulized albuterol delivered through an NHF circuit on respiratory system mechanics as compared to Standard-nebulization using a jet nebulizer with a facial mask and NHF delivered without inhaled albuterol in a randomized controlled fashion.

Methods
The study was approved by the institutional review board (Comité de Protection des Personnes Ouest-1, 2016-R6-PHAO15-SE/Airvoneb-2016-A00064-47, NCT02812979). Adult patients with reversible obstructive lung disease defined as a baseline of forced expiratory volume in one second (FEV1) over vital capacity ratio below 70% and a positive bronchodilator reversibility test (FEV1 increase of at least 12% and 200 mL after inhaled albuterol delivery [19]) as assessed in the past month were included after written informed consent. Non-inclusion criteria were ongoing exacerbation, hemoptysis, uncontrolled asthma, recent pneumothorax, lung or pleural biopsy, broncho-alveolar lavage, pregnancy, breast feeding, trusteeship, guardianship and albuterol allergy or intolerance. Patients underwent, on three separate days within 1 week, in a randomized order: (1) albuterol nebulization through a facial aerosol mask (Standard-nebulization), (2) albuterol nebulization within an NHF circuit (NHF-nebulization) and (3) sham nebulization within an NHF circuit (Control-NHF). Patients were instructed not to smoke or to take short- or long-acting bronchodilators, respectively 4, 6 and 12 h prior to each procedure.

Standard-nebulization
2.5 mg albuterol (albuterol sulphate 2.5 mg/2.5 mL, Mylan N.V., Canonsburg, PA, USA) was placed in a jet nebulizer connected to a bucco-nasal facial mask positioned on the patient and driven with 6 L/min of non-heated and non-humidified pressurized air (Cirrus2 nebulizer and Adult EcoLite™ Aerosol Mask, both from Intersurgical, Wokingham, UK).

NHF-nebulization
2.5 mg albuterol was placed in a vibrating mesh nebulizer (Aerogen Solo®, Aerogen Ltd., Galway, Ireland) positioned immediately downstream of the humidification chamber of an NHF system (Airvo™2, Fisher & Paykel Healthcare, Auckland, New Zealand), using the Airvo™Neb connector (Fig. 1). NHF was set at 30 L/min of air with 100% relative humidity at 37 °C using medium size nasal cannula. The NHF session lasted 30 min, and nebulization was started after 10 min of NHF therapy.

Control-NHF
The patient was placed under NHF during 30 min in the same conditions as for NHF-nebulization with an empty nebulizer. The patient was kept blind between the NHF-nebulization and Control-NHF procedures.

The primary outcome was the relative increase in FEV1 after NHF-nebulization as compared to Standard-nebulization. Pulmonary function tests (spirometry and plethysmography; calibrated Jaeger MasterScreen body plethysmograph, Spirometry SentrySuite v2.10, CareFusion, Rolle, Switzerland) were performed before and after each procedure, according to guidelines [19]. Spirometry was started immediately after the end of the 30 min NHF sessions, at least 10 min after the end of nebulization. Pulmonary function tests were performed following...
the same time span after the end of NHF therapy in both conditions comprising NHF (NHF-nebulization and Control-NHF) and following the same time span after the end of nebulization in both conditions comprising active nebulization (Standard-nebulization and NHF-nebulization).

Plethysmography loops were evaluated, and patients were classified as presenting expiratory flow limitation or not [20, 21]. Volumetric capnography was performed before and after each procedure (5 duplicate measurements, patients breathing out at slow and steady flow from maximal inspiration to maximal expiration) and the slope of the third phase of the capnogram measured. All pulmonary function tests were performed and interpreted by investigators and technicians blind to the procedure randomization. Patients’ comfort was recorded using a visual analogical scale (range 0–100, with higher scores indicating higher comfort). The NHF-nebulization set-up and vibrating mesh nebulizer performance were tested in vitro prior to the clinical study (see Additional file 1).

Statistical analysis
The sample size calculation was based on previous data which showed a standard deviation of FEV1 of 10% of the baseline value [22]. Taking into account the cross-over design, this non-inferiority trial, testing the hypothesis that NHF-nebulization is non-inferior to Control-nebulization in terms of FEV1 relative increase, with a non-inferiority margin of 8%, a unilateral alpha risk of 2.5% and a beta risk of 10%, had to enrol 24 patients.

An association between the randomization order and primary outcome was assessed looking for interaction between the relative increase in FEV1 and the procedure position to rule out a carry-over or learning effect on pulmonary function tests (nonparametric Kruskal–Wallis test). To partition the increase in FEV1 potentially due to NHF alone from the pharmacological effect of albuterol nebulization, the FEV1 increase attributable to albuterol nebulization was calculated individually, by subtracting Control-NHF-induced absolute FEV1 increase from NHF-nebulization-induced absolute FEV1 increase.

Quantitative variables were expressed as median and interquartile range and were compared before and after each procedure using a Wilcoxon signed rank test. Individual changes (before/after the procedure) were compared between procedures (Standard-nebulization, NHF-nebulization and Control-NHF) using the non-parametric Friedman test accounting for the cross-over design, and if significant, two-by-two comparisons were performed with the Wilcoxon signed rank test. Correlation between quantitative variables was evaluated with the Spearman correlation coefficient. Qualitative variables were expressed as counts and percentages. The agreement between Standard-nebulization and NHF-nebulization in terms of airway obstruction reversibility (200 mL absolute and 12% relative increase in FEV1 [19]) was assessed using the kappa coefficient. A p value < 0.05 was considered significant.

Results
In vitro results are presented in the Additional file 1. From June 2016 to April 2018, 11,288 patients underwent pulmonary function tests, 4905 spirometry with plethysmography, and beta-2-adrenergic agonist-induced reversibility was tested in 3552 patients of which 25 were included (Table 1).

**FEV1 change**
After Standard-nebulization, FEV1 significantly increased from 1.77 L (1.43; 2.16) to 2.20 L (1.69; 2.47), p < 0.0001 (Table 2). Individual absolute and relative increases in FEV1 were, respectively, 350 mL (180; 550) and 18% (8; 30). NHF-nebulization similarly induced a significant FEV1 increase: 1.77 L (1.47; 2.27) to 2.14 L (1.71; 2.41), p < 0.0001, with individual absolute and relative increases of 330 mL (140; 390) and 16% (5; 24): Fig. 2.

After Control-NHF without bronchodilator delivery, FEV1 increased from 1.83 L (1.36; 2.42) to 1.93 L (1.27; 2.52), p = 0.044: Fig. 2. Median individual absolute and

### Table 1 Patients’ baseline characteristics

| Variable                                      | N = 25 |
|-----------------------------------------------|--------|
| Female/male                                   | 10 (40%)/15 (60%) |
| Age (years)                                   | 60 (53; 68) |
| Main respiratory disease                      |        |
| Asthma                                        | 9 (36%) |
| COPD                                          | 14 (56%) |
| Other                                         | 2 (8%)  |
| Height (cm)                                   | 169 (165; 176) |
| Weight (kg)                                   | 75 (64; 80) |
| Body mass index (high/weight²)                | 26 (23; 29) |
| FEV1 (L)                                      | 1.83 (1.38; 2.03) |
| Percentage of predicted (%)                   | 60 (53; 71) |
| FEV1/vital capacity (%)                       | 54 (45; 60) |
| Functional residual capacity (L)              | 5.0 (3.9; 6.0) |
| Percentage of predicted (%)                   | 150 (139; 171) |
| Residual volume (L)                           | 4.0 (2.9; 4.4) |
| Percentage of predicted (%)                   | 172 (154; 184) |
| Presence of expiratory flow limitation         | 6 (24%) |

Data are presented as count (percentage) and median (interquartile range)

**COPD** chronic obstructive pulmonary disease, **FEV1** forced expiratory volume in one second
relative increases were 50 mL (−10; 220) and 3% (−1; 8): Table 2.

No interaction was observed between the randomization order of the procedures and the absolute and relative increase in FEV\textsubscript{1} (p = 0.66 and p = 0.59, respectively). There was an overall statistically significant difference between procedures for the absolute and relative increase in FEV\textsubscript{1} (p < 0.001 and p = 0.001, respectively). In two-by-two comparisons, changes in FEV\textsubscript{1} after NHF-nebulization and Standard-nebulization were not significantly different (Fig. 2) and well correlated (Fig. 3) and exhibited low bias (Figure E3 of the Additional file 1). Changes in FEV\textsubscript{1} after Control-NHF were significantly lower (Fig. 2). Of note, when calculating changes attributable to albuterol nebulization during NHF-nebulization (subtracting Control-NHF-induced changes from NHF-nebulization-induced changes), the individual absolute increase in FEV\textsubscript{1} attributable to albuterol nebulization was 230 mL (−45; 385), a value significantly lower than the FEV\textsubscript{1} increase after Standard-nebulization (p = 0.009).

### Table 2 Spirometry, plethysmography and volumetric capnography results

| Procedure            | Before | After | Individual change | Before | After | Individual change | Before | After | Individual change |
|----------------------|--------|-------|-------------------|--------|-------|-------------------|--------|-------|-------------------|
| NHF-nebulization      |        |       |                   |        |       |                   |        |       |                   |
| FEV\textsubscript{1} (L) | 1.77   | 2.20  | 0.350 (0.180; 0.550) | 1.77   | 2.14  | 0.330 (0.140; 0.390) | 1.83   | 1.93  | 0.050 (−0.010; 0.220) |
| Functional residual volume (L) | 4.58 (3.89; 5.22) | 4.07 (3.42; 4.88) | −0.33 (−0.71; −0.17) | 4.42 (3.67; 5.35) | 4.04 (3.45; 5.09) | −0.64 (−0.64; −0.12) | 4.58 (3.80; 5.38) | 4.42 (3.72; 5.53) | −0.02 (−0.24; 0.10) |
| Residual volume (L)    | 3.42 (2.63; 4.22) | 2.89 (2.42; 3.54) | −0.37 (−0.82; −0.12) | 3.22 (2.53; 4.29) | 2.90 (2.52; 4.20) | −0.34 (−0.64; −0.06) | 3.27 (2.76; 3.99) | 3.19 (2.72; 4.56) | −0.09 (−0.34; 0.16) |
| Forced vital capacity (L) | 3.57 (2.66; 4.39) | 3.65 (3.15; 4.59) | 0.32 (0.08; 0.57) | 3.41 (2.79; 4.37) | 3.51 (3.05; 4.47) | 0.11 (0.00; 0.34) | 3.28 (2.74; 4.52) | 2.84 (2.64; 4.42) | 0.10 (−0.10; 0.25) |
| Plethysmographic airway resistances (raw) | 5.31 (3.72; 6.94) | 2.89 (2.54; 3.80) | −2.06 (−3.82; −0.96) | 4.62 (3.48; 7.27) | 3.10 (2.39; 3.79) | −1.89 (−3.36; −0.69) | 4.71 (3.22; 7.02) | 2.86 (2.86; 5.77) | −0.39 (−1.02; 0.04) |
| Inspiratory capacity (L) | 2.36 (2.03; 2.71) | 2.63 (2.26; 3.34) | 0.30 (0.14; 0.54) | 2.59 (2.12; 2.90) | 2.72 (2.17; 3.17) | 0.20 (0.05; 0.47) | 2.21 (1.78; 2.97) | 2.61 (1.93; 2.91) | 0.10 (−0.07; 0.20) |
| Part III of the volumetric capnography slope (n = 16) | 0.56 (0.47; 0.74) | 0.66 (0.51; 0.92) | 0.04 (−0.03; 0.13) | 0.67 (0.41; 0.94) | 0.64 (0.40; 0.98) | 0.03 (−0.11; 0.08) | 0.62 (0.47; 0.89) | 0.65 (0.45; 0.91) | 0.01 (−0.05; 0.12) |

Standard-nebulization consisted in 2.5 mg albuterol delivery with a jet nebulizer connected to an aerosol facial mask; NHF-nebulization: 2.5 mg albuterol delivered within a nasal high-flow (NHF) circuit; Control-NHF: nasal high flow without nebulization

FEV\textsubscript{1} forced expiratory volume in one second, NHF nasal high-flow

*p < 0.05 for individual changes before and after each session with one technique

### Airflow obstruction reversibility

Of the 18 patients with an increase in FEV\textsubscript{1} of more than 200 mL after Standard-nebulization during study measurements, 14/18 (78%) also showed such an increase after NHF-nebulization. Seventeen patients had an increase in FEV\textsubscript{1} of more than 200 mL after Standard-nebulization during study measurements, 14/18 (78%) also showed such an increase after NHF-nebulization. Combining both criteria according to guidelines (absolute and relative increase in FEV\textsubscript{1}) [19], 16 patients met the criteria for airflow obstruction reversibility after albuterol Standard-nebulization during study measurements, all but two of these (n = 14/16, 88%) met the criteria after albuterol NHF-nebulization; conversely, all but one of the patients meeting the criteria after NHF-nebulization (13/14 93%) did so after Standard-nebulization (kappa 0.60, 95% confidence interval 0.29–0.90).

Of note, after Control-NHF, 8/25 patients (32%) had an FEV\textsubscript{1} increase of at least 200 mL and 5/25 (20%) of at least 12%. Five patients (20%) met the criteria for airflow obstruction reversibility after Control-NHF without the addition of a bronchodilator drug [19]. See Additional file 1: Table E2 for details on those patients. No association was observed between expiratory flow limitation observed on plethysmographic loop inspection (observed in 6 patients) and positive response in terms of FEV\textsubscript{1}.
increases after Control-NHF, as only one flow limited patient showed such a positive response.

Other pulmonary function tests
Plethysmography showed significant improvement in lung volumes after Standard-nebulization and NHF-nebulization (Table 2). Significant individual reduction in functional residual capacity was observed after NHF-nebulization: from 4.42 L (3.67; 5.35) to 4.04 L (3.45; 5.09)—individual changes −400 mL (−640; −120), p = 0.001. This change was correlated with changes in residual volume observed after Standard-nebulization: Fig. 3. When NHF was delivered without albuterol nebulization, no such significant volume changes occurred (Table 2). Significant changes in plethysmography-measured airway resistances also occurred after Standard-nebulization, NHF-nebulization and Control-NHF (Table 2). The third part of the expired volumetric capnogram, which could be measured for all procedures in sixteen patients, did not show a significant change after either procedure, and individual changes were not significantly different between procedures (p > 0.05).

Tolerance
Overall tolerance of the NHF therapy and nebulization was excellent. No side effects were recorded during NHF-nebulization; one patient complained of moderate reversible dyspnoea during Standard-nebulization and during Control-NHF. No clinically significant changes in heart rate and respiratory rate occurred; individual changes were not statistically different between procedures (data
not shown). Comfort, as measured by the visual analogical scale, was not significantly different between procedures, 85 (77; 96), 85 (65; 93) and 82 (66; 92) for Standard-nebulization, NHF-nebulization and Control-NHF, respectively (p = 0.34).

Discussion
In patients with reversible obstructive pulmonary disease, away from an exacerbation, albuterol delivered by vibrating mesh nebulization through an NHF circuit appeared non-inferior to standard facial mask jet nebulization in terms of FEV$_1$ increase. This was in part due to a small but a significant increase in FEV$_1$ due to NHF without the addition of bronchodilator nebulization. To the best of our knowledge, this is the first controlled study in adults documenting clinical efficacy of nebulization within an NHF circuit adequately controlling for all confounding factors. These results have important clinical implications. As the use of NHF is expanding, physicians will increasingly be faced with patients undergoing NHF and requiring inhaled bronchodilator therapy [23]. Given the lack of controlled data, interrupting NHF therapy to deliver the inhaled medication may currently be the preferred option; these results show that albuterol can be delivered within the NHF circuit with the same efficacy and tolerance avoiding cumbersome equipment switches. These results are in line with the study of Bräunlich et al. who used a homecare NHF device to deliver a combination of albuterol and ipratropium bromide placing a jet nebulizer close to the nasal cannula but lacked a control group without nebulization [24]. Of note, positioning the nebulizer close to the nasal cannula may be suboptimal, as it favours aerosol deposition in the cannula. This deposition reduces drug delivery to the patient but was also associated with aerosol nasal dripping which may impact patients’ comfort [11]. Our results provide controlled evidence supporting the observation made by Morgan et al. of efficient albuterol delivery after nebulization within a NHF circuit set-up similar to the present one among children with acute bronchiolitis [18].

Effects of NHF without bronchodilator nebulization on pulmonary function tests are of complex interpretation. We observed a statistically significant increase in FEV$_1$ after Control-NHF, albeit modest in magnitude (median increase of 50 mL and 3%, values below validated thresholds to define reversibility [19]); this result supports the hypothesis of an NHF-induced bronchodilation. Interestingly, 20% of the patients showed significant increases in FEV$_1$ after Control-NHF meeting guideline criteria for airflow obstruction reversibility without having received a bronchodilator. Of note, FEV$_1$ was measured after interruption of NHF in patients breathing spontaneously unlike other physiological studies which observed an increase in lung volumes measured during NHF therapy [25]. This may also explain the lack of association between flow limitation and FEV$_1$ increase after Control-NHF. Plethysmography-measured lung volumes were not significantly affected by NHF in the present study. One can speculate on potential mechanism such as positive airway pressure and improved mucus hydration during the 30-min NHF session leading to the significant increase in FEV$_1$ once the therapy is interrupted. Indeed, improved mucus clearance may lead to improved lung mechanics; however, no major cough and expectoration was observed among the included patients. NHF may also induce changes in respiratory pattern potentially leading to higher tidal volume and eventually to deeper inspiration during spirometry manoeuvres. Such mechanisms will need to be investigated in the future, particularly given the ongoing studies evaluating NHF among patients suffering obstructive pulmonary disease. This study has important limitations. Only stable patients were included; thus, extrapolation to the acute care setting of unstable decompensated patients warrants evaluation. Results cannot be extrapolated to other pharmacological classes, as the favourable results observe here in terms of nebulization efficiency during NHF are due in part to the large therapeutic index of albuterol [26]. Deposition studies performed in humans suggest other drugs like antibiotics are unlike effective when inhaled through an NHF circuit [17]. Clinical efficacy studies are required in intensive care unit, emergency department and pulmonology ward patients. Two different nebulizers were used in the study. We aimed to compare usual practice (facial mask jet nebulization) to the new modality of NHF-nebulization using a vibrating mesh nebulizer. Jet nebulization within the NHF circuit, albeit feasible, comes with important limitations as the gas driving the nebulizer interferes with the NHF oxygen content, humidity and temperature. Vibrating mesh facial mask nebulization is currently of uncommon practice. Thus, the potential limit of using different nebulizers represents a pragmatic choice favouring clinical applicability of the results. Using jet nebulization in combination with nasal high-flow therapy would need further evaluation. Of note, the study did not comprise a condition of sham jet nebulization to delineate individual effect of beta-2-adrenergic agonist nebulization per se. Only one NHF setting (temperature, flow rate, cannula size) and one dose of albuterol were evaluated clinically. However, results in other conditions, tested in the bench study, can give indications of potential dose adjustments, in case of nebulization with higher flow rates for example. The significantly improved delivery observed in vitro with
Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the institutional review board (Comité de Protection des Personnes Ouest-1, 2016-R6-PHAO15-SE/Airvoneb-2016-A00064-47, NCT02812979). All patients were included after written informed consent.

Funding
The study was funded by an unrestricted grant from Fisher & Paykel Healthcare Limited, Auckland, New Zealand. Nebulizers were provided free of charge by Aerogen Limited, Galway, Ireland.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 15 October 2018 Accepted: 11 December 2018 Published online: 20 December 2018

Additional file

Additional file 1. In vitro testing and additional clinical results.

Abbreviations
NHF: nasal high-flow; FEV1: forced expiratory volume in one second; Standard-nebulization: albuterol nebulization through a facial aerosol mask; NHF-nebulization: albuterol nebulization within a nasal high-flow circuit; Control-NHF: sham nebulization within a nasal high-flow circuit.

Authors' contributions
FR, LV, VG, LP and SE were involved in study design and conception. FR, LV, LBC, DLP, CSG, MC, PFDe, LP and SE contributed to in vitro and clinical data acquisition. FR, LV, LP and SE analysed and interpreted the data. SE drafted the manuscript. FR, LV, LBC, VG, DLP, CSG, MC, PFDe, LP and SE reviewed the manuscript for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements
The authors sincerely thank Helene Bansard and Lysiane Brick from the Centre d’Investigation Clinique, INSERM U1415, CHRU de Tours, Tours, France, for their invaluable help to carry out the study, gathering data and organizing study logistics, Sylvie Angelliaume, Agnes Bauge, Nathalie Rouillard and Nathalie Jean from the Service de pneumologie et d’explorations fonctionnelles respiratoires, CHRU de Tours, Tours, France.

Disclosure of interest
SE declares consultancies fees from Aerogen, Baxter healthcare and La Diffusion Technique Francaise, research support from Aerogen, Fisher & Paykel and Hamilton, travel expenses reimbursement from Aerogen and Fisher & Paykel. Others authors declare that they have no competing interests.

Availability of data and materials
The data sets used and/or analysed during the current study are available from the corresponding author on reasonable request.

References
1. Frat JP, Thille AX, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:2185–96.
2. Zhu Y, Yin H, Zhang R, Wei J. High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients with acute respiratory failure: a systematic review and metaanalysis of randomized controlled trials. BMC Pulm Med. 2017;17:201.
3. Ehrmann S, Roche-Campo F, Bodet-Contentin I, Razazi K, Dugernier J, Trenado-Alvarez J, et al. Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients. Intensive Care Med. 2016;42:192–201.
4. Pisanis L, Vaga ML. Use of nasal high flow in stable COPD: rational and physiology. COPD. 2017;14:346–50.
5. Sopletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen therapy in adults: mechanisms of action and clinical implications. Chest. 2015;148:253–61.
6. Pisanis L, Fasano L, Corcione N, Comellini V, Musti MA, Brandao M, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax. 2017;72:373–5.
7. Onodera Y, Akimoto R, Suzuki H, Okada M, Nakane M, Kawamata K. A high-flow nasal cannula system with relatively low flow effectively washes out CO2 from the anatomical dead space in a sophisticated respiratory model made by a 3D printer. Intensive Care Med Exp. 2018;6:7.
8. Möller W, Feng S, Domanski U, Franke KJ, Celik G, Bartenstein P, et al. Nasal high flow reduces dead space. J Appl Physiol. 2017;122:191–7.
9. Vargas F, Saint-Leger M, Boyer A, Bui NH, Hilbert G. Physiologic effects of high-flow nasal cannula oxygen in critical care subjects. Respir Care. 2015;60:1369–76.
10. Fraser JF, Spooner AJ, Dunster KR, Amstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax. 2016;71:759–61.
11. Réminiac F, Vecellio L, Heuzé-Vourc’h N, Petitcollin A, Respaud R, Cabrera M, et al. Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv. 2016;29:134–41.
12. Bhatshyam AR, Wolf MT, Marcinkowski AL, Saville A, Thomai K, Caccillo JA, et al. Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv. 2008;21:181–8.
13. Ari A, Harwood R, Sheard M, Dailey P, Fink JB. In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol. 2011;46:795–801.
14. Sunbul FS, Fink JB, Harwood R, Sheard MM, Zimmerman RD, Ari A. Comparison of HFNC, bubble CPAP and SiPAP on aerosol delivery in neonates: an in vitro study. Pediatr Pulmonol. 2015;50:1099–106.
15. Dailey PA, Harwood R, Walsh K, Fink JB, Thayer T, Gagnon G, Ari A. Aerosol delivery through adult high flow nasal cannula with heliox and oxygen. Respir Care. 2017;62:1186–92.
16. Réminiac F, Vecellio L, Loughlin RM, Le Pennec D, Cabrera M, Heuzé-Vourc'h N, et al. Nasal high flow nebulization in infants and toddlers: an in vitro and in vivo scintigraphic study. Pediatr Pulmonol. 2017;52:337–44.
17. Dugernier J, Hesse M, Jumetz T, Bialais E, Roeseler J, Depoortere V, et al. Aerosol delivery with two nebulizers through high-flow nasal cannula: a randomized cross-over single-photon emission computed tomography study. J Aerosol Med Pulm Drug Deliv. 2017;30:549–558.
18. Morgan SE, Mosakowski S, Solano P, Hall JB, Tung A. High-flow nasal cannula and aerosolized β agonists for rescue therapy in children with bronchiolitis: a case series. Respir Care. 2015;60:e161–5.
19. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.
20. Radovanovic D, Pecchiari M, Pirracchio F, Zilianti C, D’Angerlo E, Santus P. Plethysmographic loops: a window on the lung pathophysiology of COPD patients. Front Physiol. 2018;9:484.
21. Tantucci C. Expiratory flow limitation definition, mechanisms, methods, and significance. Pulm Med. 2013;2013:749860. https://doi.org/10.1155/2013/749860.
22. Nava S, Karakurt S, Rampulla C, Braschi A, Fanfulla F. Salbutamol delivery during non-invasive mechanical ventilation in patients with chronic obstructive pulmonary disease: a randomized, controlled study. Intensive Care Med. 2001;27:1627–35.
23. Stefan MS, Eckert P, Tiri B, Frederici J, Lindenauer PK, Steingrub JS. High flow nasal oxygen therapy utilization: 7-year experience at a community teaching hospital. Hosp Pract. 2018;46:73–6.
24. Bräunlich J, Wirtz H. Oral versus nasal high-flow bronchodilator inhalation in chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv. 2018;31:248–54.
25. Mauro T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2017;195:1207–15.
26. Dhand R, Duarte AG, Jubran A, Jenne JW, Fink JB, Fahey PJ, et al. Dose response to bronchodilator delivered by metered dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med. 1996;154:388–93.